Format

Send to

Choose Destination
J Pharm Sci. 2017 Sep;106(9):2727-2738. doi: 10.1016/j.xphs.2017.04.057. Epub 2017 May 4.

Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologically Based Pharmacokinetic Modeling.

Author information

1
Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, Yokohama, Japan. Electronic address: kota.toshimoto@riken.jp.
2
Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, Yokohama, Japan; Clinical Pharmacology Research Laboratory, Yokohama University of Pharmacy, Yokohama, Japan.
3
Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, Yokohama, Japan.

Abstract

Hypothetical substrates undergoing transporter-mediated hepatic uptake, metabolism, and enterohepatic circulation with different rate-determining processes with a combination of inhibition constants (Ki) for hepatic uptake, metabolism, and biliary excretion processes were generated with a constant Ki for uptake and incorporated into a physiologically based pharmacokinetic model. Analyses of the kinetic model suggested that the fraction of substrates excreted in the bile to the total elimination by the liver (fbile) can be estimated under certain conditions from kinetic analyses of their blood concentration-time profiles. Using the generated time profiles of substrates with and without coadministration of inhibitors, various pharmacokinetic parameters involving fbile and Ki for the hepatic uptake, metabolism, and biliary excretion of drugs were back-calculated by fitting. Comparing parameters obtained with the original parameter sets by fitting, the Ki were found to be well estimated under the following conditions: the initial estimates for inhibition constants were relatively good, which corresponds to the case for obtaining reliable in vitro inhibition constants. In conclusion, the integration of top-down analyses with bottom-up estimates (experimental determination) of inhibition constants can be used to estimate in vivo inhibition constants and fbile reliably.

KEYWORDS:

Monte Carlo; biliary excretion; biliary recycling; drug interactions; hepatic metabolism; hepatic transport; in vitro–in vivo correlations (IVIVC); nonlinear regression; physiologically based pharmacokinetic modeling

PMID:
28479365
DOI:
10.1016/j.xphs.2017.04.057
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center